The focus of my research group is on alternative splicing. Alternative splicing is the main process through which genes can express multiple protein isoforms. ~94% of human protein-coding genes are alternatively spliced and it is estimated that ~15% of all disease-associated mutations in humans affect alternative splicing.
Current and recent projects
- Involvement and targeting of the SR protein kinases SRPK1 and CLK1 in cancer
- Alternative splicing of VEGF, HER2, ERG, and the Insulin Receptor
- Cellular adaptation to hypoxia through regulated alternative splicing
- The role of ERG and its splice isoforms in prostate and other types of cancer
- Function of stress-induced Arabidopsis mRNA-binding proteins atGRP7/8/2
- Function of Chlamydomonas reinhardtii RNA-binding protein CrGRP1 in stress adaptation
- Textbook: The Molecular Biology of RNA. Elliott and Ladomery. First edition published in 2011, Oxford University Press. Second edition published in 2016. Primers version to be published in 2023.
Latest five papers
Click on the title to view the abstract.
SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia
British Journal of Biomedical Science 80:1-10 (2023)
CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer
Scientific Reports 11:7963 (2021)
APC and AXIN2 Are Promising Biomarker Candidates for the Early Detection of Adenomas and Hyperplastic Polyps
Cancer Informatics 19: 1–8 (2020)
WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1
Biochimica et Biophysica Acta - Gene Regulatory Mechanisms 1863: 194642 (2020)
Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer
Br J Cancer 123: 1024-1032 (2020)
Interested in a self-funded PhD, or in a industrial partnership PhD?
From time to time, depending on grants, PhD studentships are available in my lab. However we are also happy to consider a self-funded (or part self-funded) PhD studentship at any time. Read more about the self-funded PhD studentship.
We also have a scheme available for companies interested in investing in research; the partnership PhD scheme, in which companies can part-fund a PhD, 50% of costs (with a current minimum of 30%).
Please contact [email protected] if interested.
External partner: We are delighted to be collaborating with Learning Deep Learning, see collaborator pages.